The specific effects of prior opioid exposure on placebo analgesia and placebo respiratory depression

被引:46
作者
Benedetti, F
Amanzio, M
Baldi, S
Casadio, C
Cavallo, A
Mancuso, M
Ruffini, E
Oliaro, A
Maggi, G
机构
[1] Univ Turin, Sch Med, Dept Neurosci, I-10125 Turin, Italy
[2] Univ Turin, Sch Med, Dept Resp Pathophysiol, Turin, Italy
[3] Univ Turin, Sch Med, Dept Thorac Surg, Turin, Italy
[4] Univ Turin, Sch Med, CIND Ctr Neurophysiol Pain, Turin, Italy
关键词
opioid; placebo analgesia; placebo respiratory depression; pain perception;
D O I
10.1016/S0304-3959(98)00010-4
中图分类号
R614 [麻醉学];
学科分类号
100217 ;
摘要
Although in most of the cases the placebo response appears to be unpredictable, several factors have been considered in order to explain the placebo analgesic effect. For example, it is widely recognized, albeit with little empirical evidence, that placebo analgesia is more likely to occur after a successful analgesic therapy. On the basis of this assumption, we tested the placebo response in a population of patients who were treated with buprenorphine the day before for relieving postoperative pain. However, due to the high variability of opioid responsiveness, buprenorphine was effective in some patients and poorly effective in some others. Similarly, buprenorphine produced respiratory depression with a large variability, ranging from mild depression to no effect. We found that the placebo analgesic response depended on the buprenorphine analgesic effectiveness of the previous day. Analogously, we found that a placebo respiratory depressant response was more pronounced in those patients with a respiratory depressant response to buprenorphine on the day before, irrespective of the analgesic effectiveness. These specific effects suggest that (1) the placebo effect is experience-dependent; (2) the mechanisms underlying placebo analgesia and placebo respiratory depression are independent from each other and, by considering the role of endogenous opioids in placebo analgesia, might involve different subpopulations of opioid receptors. (C) 1998 International Association for the Study of Pain. Published by Elsevier Science B.V.
引用
收藏
页码:313 / 319
页数:7
相关论文
共 45 条
[1]  
[Anonymous], BUPRENORPHINE COMBAT
[2]  
[Anonymous], PLACEBO THEORY RES M
[3]  
[Anonymous], PLACEBO THEORY RES M
[4]  
[Anonymous], 1985, PLACEBO THEORY RES M
[5]   MULTIPLE INTRAMUSCULAR INJECTIONS - MAJOR SOURCE OF VARIABILITY IN ANALGESIC RESPONSE TO MEPERIDINE [J].
AUSTIN, KL ;
STAPLETON, JV ;
MATHER, LE .
PAIN, 1980, 8 (01) :47-62
[6]   THE POWERFUL PLACEBO [J].
BEECHER, HK .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1955, 159 (17) :1602-1606
[7]   The neurobiology of placebo analgesia: From endogenous opioids to cholecystokinin [J].
Benedetti, F ;
Amanzio, M .
PROGRESS IN NEUROBIOLOGY, 1997, 52 (02) :109-125
[8]   Blockade of nocebo hyperalgesia by the cholecystokinin antagonist proglumide [J].
Benedetti, F ;
Amanzio, M ;
Casadio, C ;
Oliaro, A ;
Maggi, G .
PAIN, 1997, 71 (02) :135-140
[9]   The opposite effects of the opiate antagonist naloxone and the cholecystokinin antagonist proglumide on placebo analgesia [J].
Benedetti, F .
PAIN, 1996, 64 (03) :535-543
[10]   POTENTIATION OF PLACEBO ANALGESIA BY PROGLUMIDE [J].
BENEDETTI, F ;
AMANZIO, M ;
MAGGI, G .
LANCET, 1995, 346 (8984) :1231-1231